Get the Stockscreener App
2.65
3.30%
-0.08
Vigil Neuroscience Inc stock is traded at $2.65, with a volume of 164.43K.
It is down -3.30% in the last 24 hours and up +36.79% over the past month.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
See More
Previous Close:
$2.73
Open:
$2.73
24h Volume:
164.43K
Relative Volume:
0.17
Market Cap:
$111.60M
Revenue:
-
Net Income/Loss:
$-82.60M
P/E Ratio:
-1.2864
EPS:
-2.06
Net Cash Flow:
$-48.61M
1W Performance:
+10.92%
1M Performance:
+36.79%
6M Performance:
-18.52%
1Y Performance:
-7.37%
1-Day Range:
$2.53
$2.76
1-Week Range:
$2.22
$2.88
52-Week Range:
$1.49
$6.06
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Name
Vigil Neuroscience Inc
Sector
Industry
Phone
857-254-4445
Address
100 FORGE ROAD, WATERTOWN
Compare VIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
2.66 | 111.60M | 0 | -82.60M | -48.61M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.53 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.11 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Initiated | William Blair | Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-18-23 | Initiated | JMP Securities | Mkt Outperform |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Sep-16-22 | Initiated | Wedbush | Outperform |
| Aug-29-22 | Initiated | H.C. Wainwright | Buy |
| Feb-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Initiated | Jefferies | Buy |
| Feb-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-01-22 | Initiated | Stifel | Buy |
View All
Vigil Neuroscience Inc Stock (VIGL) Latest News
VIGL Stock Update: Vigil Neuroscience Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
The Attractiveness of Investing In Vigil Neuroscience Inc (VIGL) is Growing - Knox Daily
Are Vigil Neuroscience Inc’shares a good deal? - US Post News
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Neurodegenerative Disease Pioneer Vigil to Reveal Latest Developments at Major Biotech Conference - StockTitan
Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment - Defense World
Vigil Neuroscience shares rise on positive Alzheimer's trial data - MSN
Guggenheim Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN
Vigil Neuroscience's (VIGL) Buy Rating Reiterated at Guggenheim - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World
HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - MarketBeat
Vigil moves into Phase II with Alzheimer's pill - The Pharma Letter
Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update) - MSN
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial By Investing.com - Investing.com South Africa
Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments - Seeking Alpha
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 - AOL
Vigil Neuroscience stock up on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience stock gains on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience Announces Positive Phase 1 Trial Results - TipRanks
Vigil Neuroscience shares rise on positive Alzheimer's trial data By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Vigil Neuroscience Reports Positive Data from its Phase 1 - GlobeNewswire
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for - The Bakersfield Californian
Vigil's Alzheimer's Drug Shows Promising Phase 1 Results with 50% Brain Biomarker Reduction - StockTitan
Vigil Neuroscience, Inc. Reports Positive Data from its Phase 1 Clinical Trial Evaluating Vv-3927 for the Potential Treatment of Alzheimer's Disease - Marketscreener.com
Glimpse Group Inc (NASDAQ: VRAR) Down -21.05% This Year: What To Expect Next - Stocks Register
Them too in TREM2: Street keeping AD Vigil - BioWorld Online
Q4 Earnings Forecast for VIGL Issued By William Blair - Defense World
Q4 Earnings Estimate for VIGL Issued By William Blair - MarketBeat
Geode Capital Management LLC Raises Position in Ballard Power Systems Inc. (NASDAQ:BLDP) - Defense World
Geode Capital Management LLC Grows Stake in Kewaunee Scientific Co. (NASDAQ:KEQU) - Defense World
Geode Capital Management LLC Purchases 66,712 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
CarGurus to Present at 27th Annual Needham Growth Conference - The Manila Times
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones - GlobeNewswire
Vigil Neuroscience Lands $40M Sanofi Investment, FDA Signals Path for Accelerated Approval - StockTitan
Vigil Neuroscience stock hits 52-week low at $1.51 By Investing.com - Investing.com South Africa
Vigil Neuroscience stock hits 52-week low at $1.51 - Investing.com
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Decrease in Short Interest - MarketBeat
Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares By Investing.com - Investing.com South Africa
Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares - Investing.com India
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 Shares - MarketBeat
VIGL stock touches 52-week low at $1.61 amid market challenges - Investing.com India
VIGL stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
Vigil neuroscience CEO Ivana Magovcevic-Liebisch acquires $8,350 in stock - Investing.com India
Vigil neuroscience CEO Ivana Magovcevic-Liebisch acquires $8,350 in stock By Investing.com - Investing.com Australia
Vigil Neuroscience stock hits 52-week low at $2.07 - Investing.com India
Vigil Neuroscience (NASDAQ:VIGL) and ProKidney (NASDAQ:PROK) Head-To-Head Contrast - Defense World
Vigil Neuroscience initiated with an Outperform at William Blair - MSN
FY2024 Earnings Estimate for VIGL Issued By William Blair - MarketBeat
Vigil Neuroscience Inc Stock (VIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vigil Neuroscience Inc Stock (VIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 19 '24 |
Buy |
1.68 |
5,000 |
8,400 |
222,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 18 '24 |
Buy |
1.67 |
5,000 |
8,350 |
217,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 05 '24 |
Buy |
2.34 |
5,000 |
11,700 |
212,687 |
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):